Forte Biosciences, Inc. (FBRX)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 0.7163 |
| Open | 0.7163 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7100 - 0.7400 |
| 52 Week Range | 0.3800 - 1.1500 |
| Volume | |
| Avg. Volume | 34,454 |
| Market Cap | 26.386M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.88 |
- Business Wire
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
- Business Wire
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
- Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
DALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update.
© 2024 Yahoo. All rights reserved.